Loading...
XJPX
4586
Market cap14mUSD
Jun 12, Last price  
61.00JPY
Name

Medrx Co Ltd

Chart & Performance

D1W1MN
No data to show
P/E
P/S
8.26
EPS
Div Yield, %
Shrs. gr., 5y
29.29%
Rev. gr., 5y
8.63%
Revenues
257m
+786.21%
169,860,000115,092,0008,350,00059,482,00029,000,000257,000,000
Net income
-806m
L-13.52%
-1,616,314,000-1,114,645,000-1,059,833,000-1,111,150,000-932,000,000-806,000,000
CFO
-803m
L-12.05%
-1,546,956,000-985,354,000-923,688,000-1,073,292,000-913,000,000-803,000,000

Profile

MedRx Co., Ltd, a pharmaceutical formulation development company, provides pharmaceutical drugs based on the transdermal absorption system in Japan. The company develops medicines based on Ionic liquid transdermal system (ILTS) and Nano-sized Colloid Transdermal System (NCTS); and researches and develops painless transdermal administration system for vaccines, nucleic acid medicines, protein medicines, etc. Its products pipeline includes MRX-4TZT, which is in phase I clinical trials for the treatment of spastic paralysis; MRX-9FLT that is in phase I clinical trials to treat chronic, cancer, and severe pain; and MRX-7MLL and MRX-6LDT that is in pre-clinical trials to treat Alzheimer's disease and chronic pain, as well as MRX-5LBT that has completed the clinical trials for the treatment of postherpetic nerve pain. MedRx Co., Ltd was incorporated in 2002 and is headquartered in Higashikagawa, Japan.
IPO date
Feb 13, 2013
Employees
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑12
Income
Revenues
257,000
786.21%
29,000
-51.25%
59,482
612.36%
Cost of revenue
961,000
1,157,619
Unusual Expense (Income)
NOPBT
257,000
(932,000)
(1,098,137)
NOPBT Margin
100.00%
Operating Taxes
4,000
2,000
1,837
Tax Rate
1.56%
NOPAT
253,000
(934,000)
(1,099,974)
Net income
(806,000)
-13.52%
(932,000)
-16.12%
(1,111,150)
4.84%
Dividends
Dividend yield
Proceeds from repurchase of equity
1,637,745
352,132
BB yield
-31.19%
-14.61%
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
2,000
30,000
22,358
Net debt
(2,056,000)
(1,805,000)
(1,078,025)
Cash flow
Cash from operating activities
(803,000)
(913,000)
(1,073,292)
CAPEX
(759)
(1,958)
Cash from investing activities
(1,958)
Cash from financing activities
1,066,000
1,639,492
356,315
FCF
311,000
(888,670)
(1,055,880)
Balance
Cash
1,977,000
1,720,000
994,025
Long term investments
79,000
85,000
84,000
Excess cash
2,043,150
1,803,550
1,075,051
Stockholders' equity
(146,000)
7,000
(1,852,204)
Invested Capital
2,316,000
1,946,000
3,068,553
ROIC
11.87%
ROCE
11.84%
EV
Common stock shares outstanding
43,468
34,778
25,363
Price
82.00
-45.70%
151.00
58.95%
95.00
-25.78%
Market cap
3,564,411
-32.12%
5,251,418
117.94%
2,409,529
-11.86%
EV
1,508,411
3,446,418
1,331,504
EBITDA
295,000
(886,435)
(1,051,719)
EV/EBITDA
5.11
Interest
Interest/NOPBT